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Abstract 
Background: Portable devices that can be used to perform colposcopy may improve cervical cancer screening in 
low- and middle-income countries (LMIC) where access to colposcopy is limited. The objective of this study was to 
systematically review the diagnostic test accuracy (DTA) of these devices for the detection of cervical intraepithelial 
neoplasia grade 2 or higher (CIN2+).
Methods: In accordance with our protocol (Prospero CRD42018104286), we searched Embase, Medline and the 
Cochrane Controlled Register of Trials up to 9/2019. We included DTA studies, which investigated portable devices 
with moderate-to-high optical magnification (≥ 6×) for colposcopy, as described in the manual for Colposcopy and 
Treatment by the International Agency for Research on Cancer, with a histopathological reference standard. We used 
the QUADAS-2 tool to assess study quality. We examined results for sensitivity and specificity in paired forest plots, 
stratified by stages in the clinical pathway. We pooled estimates of test accuracy for the index test, used as an add-on 
to other tests, using a bivariate random-effect model.
Results: We screened 1737 references and assessed 239 full-text articles for eligibility. Five single-gate DTA studies, 
including 2693 women, met the inclusion criteria. Studies evaluated two devices (Gynocular™ and Pocket) at different 
stages of the screening pathway. In three studies, which used the index test in an add-on capacity in 1273 women, 
we found a pooled sensitivity of 0.79 (95% CI 0.55–0.92) and specificity of 0.83 (95% CI 0.59–0.94). The main sources of 
bias were partial verification, incorporation and classification bias.
Conclusion: Few studies have evaluated portable devices able to perform colposcopy, so their accuracy for the 
detection of CIN2+ remains uncertain. Future studies should include patient-relevant and long-term outcomes, 
including missed cases, overtreatment, residual and recurrent disease. To meet the challenge of eliminating cervical 
cancer in LMIC, methods for visual assessment of the cervix need urgent redress.
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Background
The World Health Organization has called for coordi-
nated global action to eliminate cervical cancer [1]. To 
achieve this goal, effective cervical screening in low- and 
middle-income-countries (LMIC), where 90% of women 
with cervical cancer live [2], is paramount. Screen-
ing strategies, which differ markedly between high- and 
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low-income countries, may contribute to this inequity. 
Systemic challenges of high costs, limited healthcare 
infrastructure for laboratory dependent screening tests, 
transportation and electricity constraints, and limited 
specialists compromise the effectiveness of screening 
programs in LMIC. Currently, cervical cancer screening 
in many LMIC is based on the cheapest method, visual 
assessment with acetic acid (VIA), with screening and 
treatment on the same day. Efforts to improve cervical 
cancer screening strategies in LMIC must consider their 
feasibility in relation to systemic factors.
Despite huge advances in cervical cancer screening 
methods, including new molecular methods like human 
papillomavirus (HPV) testing [3], visual assessment of 
the cervix remains essential for screening for pre-can-
cerous lesions. In high-income countries, colposcopy 
methods remain fundamentally important in the screen-
ing pathway [4]. Colposcopy is an advanced method of 
visual inspection that allows detailed assessment of the 
cervix [5]. A full colposcopy examination, as described 
in the manual for Colposcopy and Treatment by the 
International Agency for Research on Cancer (IARC), 
includes assessment of the cervix with low- and high 
magnification of at least 6–15×, assessment with acetic 
acid, Lugol’s iodine, assessment with white and/or green 
light [5]. Colposcopy assessment in high-income settings 
is used both to direct biopsies and to make treatment 
decisions, which rely on accurate assessment of the site 
and size of a lesion. High-income countries, which have 
had the greatest success in reducing the burden of cer-
vical cancer, employ a multi-step pathway of screening, 
treatment and follow-up [6, 7]. Colposcopy is usually 
performed after a positive screening test(s), as an ‘add-on’ 
test. The population receiving colposcopy therefore has 
a higher disease prevalence than the population receiv-
ing the first test (‘first-line’ test) in the screening pathway. 
Furthermore, women wait for the results of their biopsies 
and only women with histopathologically confirmed dis-
ease are treated.
Extensive screening and treatment pathways that 
require multiple clinic visits are not feasible in most 
LMIC. Stationary colposcopy, HPV testing, Papanicolaou 
(PAP) smears and histopathological confirmation are 
generally not used. Currently, in most LMIC a naked eye 
examination (VIA) is used for screening and treatment. 
In Africa, healthcare professionals with varying expertise 
often perform screening and studies report a wide range 
of sensitivity for VIA from 25.0 (95% CI 7.1–59.1) [8] to 
94.4% (95% CI 84.6–98.8) [9]. The scale up of screening 
programs in LMIC could benefit from improved meth-
ods of visual assessment, particularly as an add-on to 
high-risk types of HPV (HR-HPV) testing, which can 
detect earlier stages of disease that are more difficult to 
detect with the naked eye. Portable devices that perform 
the functions of stationary colposcopes could improve 
visual assessment of the cervix in settings with fluctuat-
ing electricity supplies and inconsistent maintenance, 
particularly for mobile clinic services. The IARC manual 
for Colposcopy and Treatment of Cervical Intraepithe-
lial Neoplasia defines 6× optical magnification as the 
minimum required for most of the work of colposcopy 
[5]. Optical magnification is the magnification that is 
achieved by the lens used. Portable devices may use digi-
tal zoom to enlarge an image captured by optical mag-
nification. Such digital enlargement reduces the image 
resolution and clarity. Portable devices with only low 
optical magnification (eg < 6×) have not been shown to 
improve the detection of cervical neoplasia, beyond what 
is achievable by VIA alone [10]. The objective of this 
study was to evaluate portable devices that could be used 
to perform colposcopy for the detection of histologically 
confirmed cervical intraepithelial neoplasia, grade 2 or 
higher (CIN2+).
Methods
We performed a systematic review of diagnostic test 
accuracy (DTA) studies. The study protocol is regis-
tered (Prospero CRD42018104286) (Additional file  1) 
and aligned with the Preferred Reporting Items for Sys-
tematic Reviews and Meta-Analyses for Diagnostic Test 
Accuracy Studies (PRISMA-DTA) [11]. We report our 
findings in accordance with these recommendations and 
include the checklist items.
Eligibility criteria
We included studies assessing portable devices that can 
be used to perform colposcopy (index test) with at least 
6× optical magnification. The colposcopic procedure had 
to meet standard colposcopy guidelines, as described 
above [5]. We only included studies evaluating devices 
that were mobile, not reliant on electricity, and could 
be used and maintained in LMIC. We excluded devices 
that achieved the required magnification by digital zoom, 
rather than optical magnification, or that assessed the 
tissue of the transformation zone and are used as alter-
natives to histology (also referred to as “visual biopsy” 
devices). As the reference standard, we required punch or 
excision biopsies for determining the presence of CIN2+.
Eligible study designs were: single-gate studies, with 
single inclusion criteria for participants, such as cross-
sectional studies and cohort studies [12, 13]; multiple-
gate studies, with two or more sets of inclusion criteria, 
such as case–control studies; randomised controlled tri-
als and cohort studies that compared the persistence or 
recurrence of disease after a test-treat scheme.
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Search strategy
We searched Ovid Embase, Ovid Medline, Cochrane 
Central Register of Controlled Trials, ClinicalTrials.gov, 
and the Food and Drug Administration (FDA) website for 
eligible studies and conference abstracts. We performed 
the first search on the 5th March 2018, and an update on 
September 5th, 2019. Our search terms included “cervi-
cal cancer, pre-cancer”, “mass screening, early detection 
of cancer”, “colposcopes, alternate colposcopes” [14], and 
“mobile, point of care systems, telemedicine, mhealth”. 
We present the full Ovid Medline search strategy in 
Additional file 2. We identified additional studies through 
backward and forward citation searching of relevant arti-
cles. We did not apply any language restrictions. Two 
reviewers (KT and ER) independently screened titles and 
abstracts for relevance. Disagreements were resolved by 
consensus or through discussion with a third reviewer 
(JB). We applied the same method to assess eligibility of 
full-text manuscripts.
Data extraction
One reviewer (KT) extracted the data into a piloted and 
standardised form. Another reviewer (ER) checked the 
data. Disagreements were resolved by consulting a third 
reviewer (JB) and reaching consensus. We extracted 
data on: study characteristics (setting, country, study 
year, publication year, study design); criteria for inclu-
sion and exclusion; participant characteristics (age, edu-
cation, smoking status, menopausal status, parity, HIV 
status); the index test (model, experience of the prac-
titioner using the device, number of practitioners using 
the device, number of eligible women getting index test, 
number who received index test, explanations for dis-
crepancies between those eligible and receiving the 
index test); the reference standard (reference standard, 
those eligible to receive reference standard, number who 
received reference standard, explanation for discrepan-
cies between in those eligible and those receiving the 
reference standard); and the reported estimates of DTA 
with confidence intervals. Where possible, we extracted 
the absolute numbers of true positives, false negatives, 
false positives, and true negatives. If these numbers were 
not reported, we derived them from reported estimates 
of test accuracy, total number of included women, and 
prevalence. We assessed performance characteristics 
of eligible devices at different levels of severity using 
the Swede score, where available. The Swede score uses 
five parameters (vessels, margins or surface, acetic acid 
uptake, iodine staining and lesion size) to standardise the 
visual assessment of cervical lesions [15]. Each parame-
ter is scored between zero and two, based on severity of 
the findings, and summed to a total score between zero 
(best) and ten (worst).
Quality assessment
We used the Quality Assessment of Diagnostic Accuracy 
Studies (QUADAS-2) checklist to assess the quality of 
the included studies [16]. We defined the risk of partial 
verification bias as low if 10% or fewer women did not 
receive the reference standard test.
Statistical analysis
We displayed sensitivity and specificity estimates in 
paired forest plots, for each test done, with correspond-
ing 95% confidence intervals. Where the Swede score was 
used, we displayed estimates stratified by each Swede 
score threshold. We described the Swede score opti-
mising sensitivity and specificity in each study. For the 
pooled sensitivity and specificity, we used the Swede 
score threshold of five, which is recommended as the 
cut-off optimising both sensitivity and specificity [17]. 
We pooled estimates of test accuracy when used as an 
add-on test (i.e. after a positive screening test) using 
a bivariate random-effect model [18]. We present this 
graphically with a hierarchic summary receiver-operating 
characteristic (HSROC) and describe the summary point, 
area under the receiver operating curve (AUC), 95% con-
fidence and prediction contours. We used STATA 14 and 
RevMan 5.0.18 for these analyses.
Results
Literature search overview
Our literature search identified 1737 unique references. 
After screening titles and abstracts, we excluded 1498 
citations and assessed the full-text of the remaining 239 
articles. We excluded 234 studies (Fig. 1). Most excluded 
studies were ineligible because the index test did not fit 
our criteria (n = 166). We excluded 23 studies of station-
ary colposcopes, 30 studies of devices with less than 6× 
optical magnification (VIA and visual inspection with 
Lugol’s iodine, smartphones, EVA™, Aviscope™, cervi-
cscan, and Magnivisualiser™), 21 studies where the full 
colposcopy procedure was not carried out (e.g. only ace-
tic acid was used as with digital cervicography devices, 
smartphones, microscopes) and 92 studies of visual 
biopsy devices (e.g. artificial intelligence technologies, 
electrical impedance spectroscopy, confocal microscopy, 
Truscreen™, and sonoelastography). Six publications 
were ineligible because test accuracy data were miss-
ing [19–24]. Seven publications were based on study 
populations already included in our analysis [17, 25–29]. 
We have presented a complete list of excluded full-text 
assessments and the reasons for their exclusion in Addi-
tional file 3.
We included five single-gate diagnostic test accuracy 
studies [12]. Table  1 shows the characteristics of these 
studies, which include 2693 women. Four of the studies 
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were conducted in LMIC (India [30], Bangladesh [31], 
Peru [32] and China [29]) and one was conducted in a 
high-income country (Sweden [33]). One study estimated 
DTA with two methods of screening [29] and another, 
for two different groups of providers (nurses/doctors) 
[31]. Four studies evaluated the Gynocular™ [30, 31, 33, 
34] and one study evaluated the Pocket device. These 
devices have 4–12× and 3–30× optical magnification, 
Fig. 1 PRISMA flow diagram of articles evaluated for inclusion and exclusion. From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group 
(2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097
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respectively. All studies carried out the full colposcopy 
procedures outlined in the IARC manual for Colposcopy 
and Treatment of Cervical Intraepithelial Neoplasia [5]. 
Investigators from two studies obtained funding from 
the manufacturer for their contribution to the study. In 
all other studies where funding was obtained, the manu-
script states that the funder did not play a role in plan-
ning and conducting research, or writing the manuscript.
The studies evaluated test accuracy at different stages 
in the screening pathway. The Pocket device was evalu-
ated as an add-on test to HPV or PAP-smear [24]. The 
Gynocular™ was evaluated as a first-line test [29] and as 
an add-on test to HPV, PAP-smear or VIA [30, 33]. In 
one study, the Gynocular™ device was used indiscrimi-
nately as a first-line test among 404 women (43%), and 
as an add-on test after VIA positivity among 528 women 
(57%) [31]. Estimates of test accuracy were not available 
separately for the two subgroups, so the results could not 
be summarised with the other study results. In studies 
assessing devices in an add-on capacity, disease preva-
lence ranged between 3.5% [30] and 35.7% [33]. In these 
studies, the colposcopic procedure followed a positive 
PAP smear and/or HPV and/or VIA test. Prevalence of 
CIN2+ in studies assessing the device and colposcopic 
procedure as a first-line test was 0.6% [29], and 4.2% [31] 
when used in either situation at two points in the screen-
ing pathway.
Test accuracy for the detection of CIN2+
Three of the four studies evaluating the Gynocular™ used 
the Swede scoring system to describe the colposcopy 
result [15]. We report sensitivity and specificity estimates 
for Swede score thresholds five and above (Fig. 2) and for 
all scores in Additional file 4. Across all studies, sensitiv-
ity decreased as Swede score threshold increased, and 
specificity increased. The Swede score that optimised 
sensitivity and specificity was calculated to be six in three 
studies in which doctors did the assessment [30, 31, 33], 
and seven in one study, where nurses did the assessment 
[31].
Figure  3 shows study estimates for sensitivity and 
specificity, stratified by stage in the clinical pathway. For 
each specific point, there were few studies. We pooled 
results from three studies, including 1273 women, which 
used the index test as an add-on to any previous test. 
We found a sensitivity of 0.79 (95% CI 0.55–0.92) and a 
specificity of 0.83 (95% CI 0.59–0.94), with an AUC of 
0.88 (0.85–0.90) (Fig.  4). However, the prediction inter-
val indicates a large degree of variation between stud-
ies and imprecision in the pooled estimate. One study 
reported sensitivity and specificity of the index test used 
as a first-line test, and found a sensitivity and specificity 
of 0.33 (95% CI 0.01–0.91) and 0.95 (95% CI 0.93–0.97), 
respectively [29]. We did not pool study estimates across 
different stages in the screening pathway.
Quality assessment
Overall, the quality of the eligible studies was moder-
ate. Assessment using the QUADAS-2 criteria identi-
fied three common areas that compromise studies in the 
domains of (1) patient selection, (2) index test, and (3) 
the reference standard Additional file 5.
In all five included studies, the sampling strategies were 
not detailed. It was unclear how the sample was derived, 
for example, whether a consecutive, random or conveni-
ence selection was used. Information about the target 
population was also missing, and no study reflected on 
whether the sample population was comparable to the 
target population. Data on excluded women were gener-
ally not available. In all studies, it was unclear whether 
selection bias influenced results.
Overall, the conduct of the index test was reasonable. 
However, in two studies (Nessa et  al. [31] and Kallner 
et  al. [33]), for 50% of women, the same assessor per-
formed stationary colposcopy, followed immediately 
after by the index test. This sequence of events might 
have influenced the assessment of the index test. Several 
important issues regarding the reference standard were 
identified. Partial verification bias was identified infour 
out of five studies but considered to to have a high risk of 
bias in three. We considered two studies, Banerjee et al. 
and Kallner et  al. [30, 33], to have a low risk of bias in 
the reference standard domain. In these studies, more 
than 90% of women who had received the index test also 
received the reference standard. In contrast, in Mueller 
et al. 63% of women received biopsy [32], in Nessa et al. 
25% of women received biopsy [31], and in Newman 
et al., only 6% of women received a biopsy [29]. Conduct 
of the reference standard was problematic in two stud-
ies due to incorporation bias, where investigators use the 
index test to determine the need for reference standard 
and final diagnosis [31, 33]. These two studies used the 
Gynocular™ to assess Swede score, and used thresholds 
of 1 + [33] and 5 + [31] to determine if a biopsy was nec-
essary. In contrast, two studies used alternative meth-
ods to indicate the need for biopsy. In Mueller et  al., 
a standard colposcopic examination to determine the 
need for biopsy and by different assessors to those per-
forming the index testing. In Newman et  al.[29], of the 
488 women who received the index test, 24 women were 
biopsied following Gynocular™ examination, and a fur-
ther seven were biopsied following a positive HPV test, 
cytology and stationary colposcopic examination. As 
such, women who were negative for the index test in this 
study had alternative tests, reducing the risks of misclas-
sification. None of the studies included verification of 
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histopathological diagnoses as a method for quality con-
trol and minimising misclassification.
Discussion
There are few diagnostic test accuracy studies of portable 
devices that can be used to perform colposcopy, so the 
sensitivity and specificity of such devices remains uncer-
tain. The five studies that we identified examined the 
Gynocular™ and Pocket devices at different stages in the 
screening pathway. When used as an add-on screening 
test, the pooled sensitivity was 0.79 (95% CI 0.54–0.92) 
and specificity was 0.83 (95% CI 0.59–0.94). One study 
that used the Gynocular™ as a first-line test found a sen-
sitivity and specificity of 0.33 (95% CI 0.01–0.91) and 
0.95 (95% CI 0.93–0.97), respectively. The main sources 
of bias identified were partial verification, incorporation, 
Fig. 2 Paired forest plot for Swede scores five to ten. TP true positive, FP false positive, FN false negative, TN true negative, CI confidence intervals
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and classification bias. Information about the target pop-
ulation and the selection of women was poorly reported, 
making it difficult to determine whether selection bias 
influenced findings.
The strengths of this systematic review are that we 
followed a pre-specified protocol, searched multiple 
electronic databases, systematically assessed quality of 
studies, and evaluated the DTA of the index test at dif-
ferent points of the screening pathway. We showed test 
accuracies for all Swede scores on paired forest plots. 
This allowed visualisation of the Swede score capacity to 
optimise either sensitivity or specificity, depending on 
the threshold used (Fig. 2 and Additional file 4).
The main limitation was that, owing to the small num-
ber of eligible studies, we were unable to do several of the 
planned analyses. There were too few studies to investi-
gate heterogeneity, using regression methods, to assess 
test accuracy at different stages in the colposcopy screen-
ing pathway (first-line, mixed, or add-on), or the influ-
ence of preceding tests (eg. HPV test versus PAP smear). 
We found no longitudinal studies assessing test accuracy 
and its subsequent effects on patient-relevant outcomes 
such as overtreatment, residual and recurrent disease. 
Comparative systematic reviews of tests with relevant 
controls according to their intended place in the screen-
ing pathway will increase understanding of the use of a 
test in a particular population. This was beyond the scope 
of the present review.
Biases in the design of the included studies make inter-
pretation of the findings uncertain. First, there was a high 
risk of partial verification bias in three of five studies 
[29, 31, 32], where less than 90% of index test recipients 
received the reference standard. Partial verification can 
result in overestimation of both sensitivity and specific-
ity if women with more subtle disease are not identified. 
Second, we found evidene of incorporation bias, where 
the investigators used the index test to determine the 
need for the reference standard. This circularity may also 
artificially increase both the sensitivity and specificity of 
estimates. Third, classification bias, which describes how 
accurately true disease is identified, was noted. The refer-
ence standard of colposcopy-directed biopsy is the best 
available option for identification of true disease in the 
studies. More invasive reference standards, for example, 
excision of the transformation zone by cone biopsy or 
Loop Electrosurgical Excision Procedure (LEEP) would 
Fig. 3 Paired forest plot of index test sensitivity and specificity stratified by clinical pathway. TP true positive, FP false positive, FN false negative, TN 
true negative, CI confidence intervals
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allow histological examination of the whole transforma-
tion zone, reducing the chance of misclassification, but 
carries unacceptable risks and potential long-term con-
sequences for women of child-bearing age [35]. Newman 
et  al. addressed potential misclassification of the refer-
ence standard by testing negative cases with alternative 
tests (HPV testing and stationary colposcopy) to mini-
mise the risk of missing disease [29]. However, we were 
concerned about the small proportion of those receiving 
the index test who also received the reference standard. 
Other measures to minimise misclassification could be 
considered, such as obtaining more than one biopsy and 
obtaining biopsy in colposcopy-negative cases. These 
measures were not reported in any of the studies despite 
a large body of evidence to suggest that a single biopsy 
may miss true disease or underestimate disease preva-
lence [36–39]. Fourth, no studies reported on quality 
control or verification of histology results.
Taking into account the limitations of the studies in this 
systematic review, our findings on the accuracy of porta-
ble colposcopes used in an add-on capacity are consistent 
with current literature in most high-income settings [4, 
14, 40]. We found a sensitivity of 0.79 (95% CI 0.55–0.92) 
and a specificity of 0.83 (95% CI 0.59–0.94), (AUC 0.88 
[95% CI 0.85–90]) for portable devices that can be used 
to perform colposcopy as an add-on test. Many LMIC 
aim to provide single-visit screening and treatment for 
women, once or twice in their lifetime. With such few 
opportunities to see women, testing should rule-out dis-
ease in order that women will not miss the opportunity 
to be treated for pre-cancerous lesions of the cervix [42]. 
Ideally, screening with a highly sensitive first-line test 
should increase the prevalence of disease in the screened 
population before the next test is applied. As long as 
prevalence is low, the predictive value of a positive test 
also remains low [43]. In one study, where the Gynocu-
lar device was used as a first-line test, sensitivity was 
0.33 (95% CI 0.01–0.91) [29]. At this level of sensitivity, 
based on the point estimate, portable colposcopes, as for 
stationary colposcopy, would not be useful as a first-line 
test. Furthermore, colposcopy is a specialized procedure 
and would be very resource intensive at this point of the 
screening pathway [40, 41]. We also found that the Swede 
score could be either highly sensitive or specific depend-
ing upon the threshold used. This supports the literature 
showing that scoring systems such as the Swede score 
can be used flexibly, to favour sensitivity or specificity, 
depending on the population and point in the screening 
pathway in which it is used [32].
We identified several alternatives and adjuncts to VIA, 
colposcopy and biopsy, though their technical specifica-
tions did not meet our inclusion criteria. We highlight 
some promising technologies for settings where skilled 
healthcare workers and laboratory facilities are scarce. 
Early studies on automated algorithms to evaluate cer-
vigrams have found that CIN2+ can be identified with 
greater accuracy (AUC 0.91 [95% CI 0.89–0.93]) than 
original cervigram interpretation (AUC 0.69 [95% CI 
0.63–0.74]) [44]. There are also emerging microscopy 
and spectroscopy devices (visual biopsy devices) that are 
mobile and may have potential in low-resource settings 
[45–48]. If evolving technologies eventually replace sta-
tionary colposcopy, these require robust evaluation, at 
defined stages in the screening pathway, and among the 
population in which they will be used.
To meet the challenge of eliminating cervical cancer in 
LMIC, studies exploring feasible methods to improve on 
current visual assessment strategies are urgently required. 
Our systematic review identifies information gaps and 
methodological issues that should be considered in future 
studies of cervical screening methods. First, the purpose 
of the test, the stage of use in the screening pathway, con-
sequences to patients, and the resources available in the 
setting should be clear. These factors are specially impor-
tant in the evaluating cervical cancer screening strategies 
because the purpose and consequences to patients differ 
significantly between high- and LMIC. In high-income 
countries, treatment follows biopsy confirmation of dis-
ease, whereas in LMIC treatment occurs in the absence 
of a confirmatory test, using an estimated risk of disease 
only. Second, randomised controlled trials should be 
used more often as they allow direct comparison of dif-
ferent screening strategies. Trials should be designed to 
assess short- and long-term patient-relevant outcomes 
including persistence or recurrence of disease. Third, 
methods to minimise bias in test accuracy studies should 
be considered. Protocols that require biopsies from most 
or all women are likely to increase the chance of correctly 
identifying cervical disease [36–39]. If this is not possi-
ble, and a study is sufficiently large, a random sample of 
low-risk patients who would not usually receive a biopsy 
could be selected for biopsy to estimate the fraction of 
false negatives. Statistical models for analysis of miss-
ing data that include all participants should lead to more 
valid estimates than simply assuming test negative results 
to be true negative results [49]. Methods to reduce mis-
classification should also be considered. For example, 
using multiple biopsies, composite reference standards, 
or following up on participants with another non-inva-
sive screening test will improve the validity of the refer-
ence test. We stress the importance of designing studies 
where the index test does not determine the need for the 
reference standard. Quality control or verification for the 
interpretation of histological specimens should also be 
considered in future studies. The emergence of improved 
cervical cancer screening methods has not eliminated the 
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need for visual assessment. Detection of HR-HPV, using 
nucleic acid amplification tests, allows identification of 
disease at an earlier stage than pre-existing strategies 
such as cytological assessment. The sub-optimal specific-
ity of HR-HPV requires some form of triaging, either to 
direct biopsies or to make treatment decisions. So opti-
cal magnification, as a point-of-care add-on test, may be 
even more important. With the current challenges of vis-
ual inspection in LMIC, more studies on portable devices 
able to perform colposcopy are required. Our literature 
review found few portable devices that can be used to 
perform colposcopy so we cannot make recommenda-
tions about specific devices in scale-up efforts. However, 
considering the central role of colposcopy in the manage-
ment of precancerous lesions, and despite the widespread 
scale-up of HR-HPV testing, more research in this area 
will be useful.
Conclusion
We did a systematic review to determine the test accu-
racy of portable devices, with at least 6× optical magnifi-
cation, that can be used for colposcopy and the detection 
of cervical neoplasia in LMIC. We found few studies 
and their results are heterogeneous. Future comparative 
studies are required to evaluate whether these devices 
improve patient-relevant outcomes including missed 
cases, overtreatment, and residual or recurrent disease in 
LMIC. To meet the challenge of eliminating cervical can-
cer in LMIC, methods for visual assessment of the cervix 
need to be improved urgently.
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